Literature DB >> 22249122

Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.

Karine Fabio1, Christophe Guillon, Carl J Lacey, Shi-fang Lu, Ned D Heindel, Craig F Ferris, Michael Placzek, Graham Jones, Michael J Brownstein, Neal G Simon.   

Abstract

SRX246 is a potent, highly selective human vasopressin V1a antagonist that crosses the blood-brain barrier in rats. CNS penetration makes SRX246 an ideal candidate for potential radiolabeling and use in visualization and characterization of the role of the V1a receptor in multiple stress-related disorders. Before radiolabeling studies, cold reference analogs of SRX246 were prepared. This study describes the synthesis and in vitro screening for human V1a receptor binding and permeability of fluoro, iodo, and methyl reference compounds for SRX246 and the preparation of a tin precursor. For each compound, the potential utility of corresponding radiolabeled analogs for PET and SPECT imaging is discussed.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22249122      PMCID: PMC3449305          DOI: 10.1016/j.bmc.2011.12.013

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  44 in total

1.  Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine.

Authors:  W J Inder; T C Prickett; R T Mulder; R A Donald; P R Joyce
Journal:  Psychopharmacology (Berl)       Date:  2001-06       Impact factor: 4.530

Review 2.  Glucocorticoids and depression.

Authors:  T Steckler; F Holsboer; J M Reul
Journal:  Baillieres Best Pract Res Clin Endocrinol Metab       Date:  1999-12

3.  V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.

Authors:  R Landgraf; R Gerstberger; A Montkowski; J C Probst; C T Wotjak; F Holsboer; M Engelmann
Journal:  J Neurosci       Date:  1995-06       Impact factor: 6.167

4.  [125I/127I]iodoHoechst 33342: synthesis, DNA binding, and biodistribution.

Authors:  R S Harapanhalli; L W McLaughlin; R W Howell; D V Rao; S J Adelstein; A I Kassis
Journal:  J Med Chem       Date:  1996-11-22       Impact factor: 7.446

5.  Azetidinones as vasopressin V1a antagonists.

Authors:  Christophe D Guillon; Gary A Koppel; Michael J Brownstein; Michael O Chaney; Craig F Ferris; Shi-Fang Lu; Karine M Fabio; Marvin J Miller; Ned D Heindel; David C Hunden; Robin D G Cooper; Stephen W Kaldor; Jeffrey J Skelton; Bruce A Dressman; Michael P Clay; Mitchell I Steinberg; Robert F Bruns; Neal G Simon
Journal:  Bioorg Med Chem       Date:  2006-12-23       Impact factor: 3.641

Review 6.  The involvement of the vasopressin system in stress-related disorders.

Authors:  Rainer Landgraf
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-04       Impact factor: 4.388

Review 7.  Vasopressin as a target for antidepressant development: an assessment of the available evidence.

Authors:  Lucinda V Scott; Timothy G Dinan
Journal:  J Affect Disord       Date:  2002-11       Impact factor: 4.839

8.  Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin.

Authors:  Alexandra Wigger; Mar M Sánchez; Kenneth C Mathys; Karl Ebner; Elisabeth Frank; Dong Liu; Adelheid Kresse; Inga D Neumann; Florian Holsboer; Paul M Plotsky; Rainer Landgraf
Journal:  Neuropsychopharmacology       Date:  2004-01       Impact factor: 7.853

9.  [Study of the stress response: role of anxiety, cortisol and DHEAs].

Authors:  M Boudarene; J J Legros; M Timsit-Berthier
Journal:  Encephale       Date:  2002 Mar-Apr       Impact factor: 1.291

10.  Imaging the neural circuitry and chemical control of aggressive motivation.

Authors:  Craig F Ferris; Tara Stolberg; Praveen Kulkarni; Murali Murugavel; Robert Blanchard; D Caroline Blanchard; Marcelo Febo; Mathew Brevard; Neal G Simon
Journal:  BMC Neurosci       Date:  2008-11-13       Impact factor: 3.288

View more
  5 in total

1.  Development of a radioligand for imaging V1a vasopressin receptors with PET.

Authors:  Ravi Naik; Heather Valentine; Andrew Hall; William B Mathews; James C Harris; C Sue Carter; Robert F Dannals; Dean F Wong; Andrew G Horti
Journal:  Eur J Med Chem       Date:  2017-08-18       Impact factor: 6.514

2.  Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging.

Authors:  Ahmed Haider; Zhiwei Xiao; Xiaotian Xia; Jiahui Chen; Richard S Van; Shi Kuang; Chunyu Zhao; Jian Rong; Tuo Shao; Perla Ramesh; Appu Aravind; Yihan Shao; Chongzhao Ran; Larry J Young; Steven H Liang
Journal:  Pharmacol Res       Date:  2021-09-16       Impact factor: 7.658

Review 3.  Positron Emission Tomography in the Neuroimaging of Autism Spectrum Disorder: A Review.

Authors:  Zhiqiang Tan; Huiyi Wei; Xiubao Song; Wangxiang Mai; Jiajian Yan; Weijian Ye; Xueying Ling; Lu Hou; Shaojuan Zhang; Sen Yan; Hao Xu; Lu Wang
Journal:  Front Neurosci       Date:  2022-04-13       Impact factor: 5.152

Review 4.  Vasopressin and oxytocin receptor systems in the brain: Sex differences and sex-specific regulation of social behavior.

Authors:  Kelly M Dumais; Alexa H Veenema
Journal:  Front Neuroendocrinol       Date:  2015-05-04       Impact factor: 8.606

Review 5.  Current and future functional imaging techniques for post-traumatic stress disorder.

Authors:  Alisha Prasad; Ardalan Chaichi; D Parker Kelley; Joseph Francis; Manas Ranjan Gartia
Journal:  RSC Adv       Date:  2019-08-08       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.